Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients

Shuichiro Takashima, Toshihiro Miyamoto, Masanori Kadowaki, Yoshikiyo Ito, Takatoshi Aoki, Ken Takase, Takahiro Shima, Goichi Yoshimoto, Koji Kato, Tsuyoshi Muta, Motoaki Shiratsuchi, Katsuto Takenaka, Hiromi Iwasaki, Takanori Teshima, Tomohiko Kamimura, Koichi Akashi

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation. In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM. VTD consisted of bortezomib at a dose of 1.3 mg/m2 and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. Peripheral neuropathy was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed. Very good partial response or better response (≥VGPR) rates before and after consolidation therapy were 54 and 79 %, respectively. Patients had a significant probability of improving from <VGPR before consolidation therapy to ≥VGPR after consolidation therapy (p = 0.041). The VTD regimen may be safe and effective as a consolidation therapy in the treatment of MM in Japanese population.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalInternational journal of hematology
Volume100
Issue number2
DOIs
Publication statusPublished - Aug 2014

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients'. Together they form a unique fingerprint.

Cite this